Skip to main content
Caplight Logo









MediMabBio

MediMabBio

Private
South KoreaHealthcare & Life Scienceshttps://medimabbio.com/

Last Round

Series B

Oct 24, 2025

Est. Valuation

$13.64M

Total Funding Raised

$38M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

MediMabBio is a biotechnology company that develops protein therapeutics, including therapeutic antibodies and fusion proteins, for the treatment of cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

fusion proteinstherapeutic antibodiesimmuno-oncologycytokine-antibody fusiondrug discovery platformprecision immune therapeuticsengineered cytokinesantibody engineeringmonoclonal antibodiesbiologics developmentautoimmune disease treatmentrational drug designTIGIT targetingbiotech licensingAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MediMabBio Comparables

Compare MediMabBio with similar companies based on industry and business-model similarity.

MediMabBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Hummingbird Bioscience
77%
Synthekine
76%
Xencor, Inc.
71%

MediMabBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 24, 2025
Series AFeb 1, 2021
Pre SeedFeb 15, 2019

Key People

Founding team and executive leadership

Eunok Kang

COO

Executive Team

MediMabBio Investors

Notable investors and investment history

MediMabBio investors
InvestorRounds
Seoul Investment PartnersSeries B
Hyundai Investment PartnersSeries B
BNH INVESTMENTSeries A, Pre Seed, Series B
Smilegate InvestmentPre Seed, Series B, Series A
iM Investment PartnersSeries B
KB InvestmentSeries B
Timefolio Asset ManagementSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors increased 273% MoM, reaching 7.1K.

  • Oct 24, 2025

    $17M round led by Hyundai Investment Partners and Timefolio Asset Management.

MediMabBio Filings

Explore SEC and related filing metadata, where available.

MediMabBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about MediMabBio's valuation, stock price, and market status.

Is MediMabBio a public or private company?

MediMabBio is a private company.

What is the current stock price of MediMabBio?

MediMabBio is a private company with no public stock price. No recent secondary market data is available.

How much is MediMabBio worth (valuation)?

Valuation information for MediMabBio is not publicly available.

Can I buy MediMabBio stock?

MediMabBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was MediMabBio's last funding round?

Funding round information for MediMabBio is not publicly available.

Who are the main investors in MediMabBio?

Investor information for MediMabBio is not publicly disclosed.

Will MediMabBio IPO soon?

No public IPO plans have been announced for MediMabBio.

How can I track MediMabBio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MediMabBio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSouth Korea
Employee Range10
Year Founded2017
Last FundingOct 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?